Premium
Rituximab‐induced serum sickness in refractory immune thrombocytopenic purpura
Author(s) -
Le Guenno G.,
Ruivard M.,
Charra L.,
Philippe P.
Publication year - 2011
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1445-5994.2010.02384.x
Subject(s) - rituximab , medicine , serum sickness , thrombocytopenic purpura , immunology , cd20 , monoclonal antibody , refractory (planetary science) , antibody , monoclonal , immune system , physics , astrobiology
Serum sickness may occur in patients treated with chimeric monoclonal antibody. Rituximab, an anti‐CD20 chimeric monoclonal antibody, is used with increasing frequency in chronic immune thrombocytopenic purpura (ITP). Rituximab is relatively safe; however, serum sickness is reported in 1‐20% of patients, more commonly among those with autoimmune conditions. We describe a case of serum sickness in a patient with ITP and review the literature of rituximab‐induced serum sickness.